Skip to main content

Biontech Se ADR(BNTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low153.75
Day High162.11
Open:160.94
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

Why Moderna and Pfizer Stocks Lagged the Market Today
Motley Fool - Mon May 23, 4:05PM CDT
Motley Fool
Mon May 23, 4:05PM CDT
Despite good regulatory news for both companies, and encouraging clinical results reported from one, investor reaction was muted.
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Globe Newswire - Mon May 23, 5:45AM CDT
Globe Newswire
Mon May 23, 5:45AM CDT
Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use AuthorizationThe...
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Business Wire - Mon May 23, 5:45AM CDT
Business Wire
Mon May 23, 5:45AM CDT
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to...

Latest Articles

BioNTech says repeat doses remain better strategy than adapting its COVID-19 vaccine to new variants